Managed Account Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

Managed Account Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$133K	Buy	2,483 +484	+24%	+$25.7K	﹤0.01%	2562
2015 Q1	$121K	Sell	1,999 -224	-10%	-$10.9K	﹤0.01%	2519
2014 Q4	$116K	Buy	+2,223	New	+$99.5K	﹤0.01%	2384

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Managed Account Advisors's JUNO Position: Q2 2015 in Review

Managed Account Advisors increased its Juno Therapeutics, Inc. (JUNO) stake by 24% in Q2 2015, buying an estimated $25.7K and bringing the position to 2,483 shares worth $133K. The position accounts for ﹤0.01% of the portfolio, ranked #2562.

Managed Account Advisors first reported a position in JUNO in Q4 2014 and has held it in 3 quarters since. 154 funds tracked by Wall St. Rank hold JUNO as of Q2 2015.

Managed Account Advisors held 2,483 shares of Juno Therapeutics, Inc. worth $133K as of Q2 2015.
Managed Account Advisors bought 484 Juno Therapeutics, Inc. shares in Q2 2015, an estimated $25.7K.
Juno Therapeutics, Inc. made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #2562 holding.
Managed Account Advisors first reported a position in Juno Therapeutics, Inc. in Q4 2014 and has held it in 3 quarters since.
154 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.